Drug Involvement of Prenatally Exposed Children

产前暴露儿童的药物参与

• 批准号: 6920604
• 负责人: VERONICA H ACCORNERO
• 金额: $ 13.36万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-01 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6920604
• 关键词: African American; adolescence (12-20); clinical research; cocaine; developmental neurobiology; disease /disorder onset; disease /disorder proneness /risk; drug abuse; early experience; embryo /fetus toxicology; human subject; middle childhood (6-11); neuropharmacology; parent offspring interaction; psychopathology

DESCRIPTION (provided by applicant): The candidate is proposing a five-year career development plan to launch independent research on the topic of prenatal drug exposure as a risk factor for earlier onset and more rapid progression through stages of drug involvement (e.g., opportunity, first use, regular use, and dependence), with due consideration for susceptibility traits and other biological, psychological, and social/environmental influences. With licensure in child clinical psychology and postdoctoral training in drug dependence epidemiology, the candidate brings to this award expertise in child and adolescent development and psychopathology, rich clinical experiences to guide and inform her research efforts, knowledge of basic statistical methods, and a strong commitment to the study of early drug involvement. The multidisciplinary training plan includes mentorship from Dr. Clyde McCoy and other experienced senior NIDA-supported investigators, coursework/workshops, conferences, and consultation from content and methodological specialists. The centerpiece of the early award-supported activities will be a supervised research project focusing on the influence of prenatal cocaine exposure on the earliest stages of drug involvement. The starting model at this stage of the research plan is based on the testable idea that cocaine-exposed children will have earlier and more frequent opportunities to use drugs and will transition more rapidly from opportunity to first use between late childhood and middle adolescence. To this end, the candidate will gather new annual data in addition to analyzing data from an ongoing, longitudinal NIDA-funded study (R01DA06556; P.I.: E.S. Bandstra, co-sponsor) on the neurodevelopmental outcome of cocaine-exposed infants, who will again be assessed at age 12 years. Relationships between prenatal cocaine exposure and early drug involvement will be examined in the context of potential mediators already measured between birth and age 12 (e.g., executive functioning/attention, behavior problems), moderators (e.g., gender), and additional influences (e.g., deviant peers, ongoing maternal drug use). The candidate's own plan calls for the addition of measures of drug opportunities and sensation seeking during the 12-year visit, with annual follow-up assessments of these constructs via telephone as the children develop through adolescence. This K01 award will enable the candidate to devote full-time effort to NIDA research, while broadening her understanding of child and adolescent drug involvement and the longitudinal research methods (xxx; P.I.: J. C. Anthony, co-sponsor) and other content areas required to understand the interplay of early susceptibilities, environmental factors, and time-dependent influences that might shape the expression of prenatal drug exposure. This enhanced knowledge will be the foundation for the candidate's planning and implementation of her independent career in drug research.

描述（由申请人提供）： 候选人提出了一个五年职业发展计划，以启动关于产前药物暴露作为早期发病和更快进展的风险因素的独立研究。机会、首次使用、定期使用和依赖性），并适当考虑易感性特征和其他生物、心理和社会/环境影响。凭借儿童临床心理学和药物依赖流行病学博士后培训的许可证，候选人为该奖项带来了儿童和青少年发展和精神病理学方面的专业知识，丰富的临床经验，以指导和告知她的研究工作，基本统计方法的知识，以及对早期药物参与研究的坚定承诺。多学科培训计划包括克莱德麦考伊博士和其他经验丰富的NIDA支持的高级研究人员的指导，课程/研讨会，会议以及内容和方法专家的咨询。早期奖项支持的活动的核心将是一个监督研究项目，重点是产前可卡因暴露对药物参与的最早阶段的影响。研究计划这一阶段的起始模式基于一个可检验的想法，即接触可卡因的儿童将有更早和更频繁的吸毒机会，并将在童年晚期和青春期中期更快地从吸毒机会过渡到首次吸毒。为此，候选人将收集新的年度数据，并分析来自一项正在进行的、由美国国家药品监督管理局资助的纵向研究的数据（R 01 DA 06556; P.I.：E.S. Bandstra，共同发起人）对可卡因暴露婴儿的神经发育结果进行评估，这些婴儿将在12岁时再次接受评估。产前可卡因暴露与早期药物参与之间的关系将在出生至12岁之间已经测量的潜在介质的背景下进行检查（例如，执行功能/注意力，行为问题），调节器（例如，性别），以及额外的影响（例如，不正常的同龄人，正在进行的孕产妇药物使用）。候选人自己的计划要求在12年的访问期间增加药物机会和感觉寻求的措施，随着孩子们在青春期的发展，每年通过电话对这些结构进行随访评估。该K 01奖将使候选人能够全职致力于NIDA研究，同时扩大她对儿童和青少年药物参与和纵向研究方法的理解（xxx; P.I.：J. C.安东尼，共同发起人）和其他内容领域需要了解的早期易感性，环境因素和时间依赖性的影响，可能塑造产前药物暴露的表达的相互作用。这种增强的知识将是候选人的规划和实施她在药物研究的独立职业生涯的基础。